Pulmonary arterial hypertension trials in Poland

In Poland 20 Also abroad 305

20 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Where
Lublin, Poznan
Age
18 years and over
People
89 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-513613-12-00 · EU 2024-513613-12-00
Phase 3Taking people
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Where
Bialystok, Bydgoszcz, Katowice, Lodz, Lublin, Poznan, Szczecin, Wroclaw
Age
2 years and over
People
280 worldwide
Run by
Actelion
See details and how to joinNCT05179876 · EU 2023-506791-27-00
Phase 2Taking people
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Where
Gdansk, Warsaw
Age
1 year to 17 years
People
42 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05587712 · EU 2023-504861-22-00
Phase 4Taking people
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Where
Cracow, Otwock, Poznan
Age
18 years to 75 years
People
110 worldwide
Run by
AOP Orphan Pharmaceuticals AG
See details and how to joinNCT06317805 · EU 2023-504351-26-01
No phaseEnrolling by invitation
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Where
Krąków, Otwock
Age
18 years and over
People
110 worldwide
Run by
AOP Orphan Pharmaceuticals AG
See details and how to joinNCT06445673
Phase 2Taking people
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Where
Krakow, Lublin, Szczecin
Age
18 years to 75 years
People
135 worldwide
Run by
NS Pharma, Inc.
See details and how to joinNCT07441200 · EU 2025-525114-38-00
Phase 2Taking people
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Where
Krakow, Lublin, Wroclaw
Age
18 years to 80 years
People
25 worldwide
Run by
Tectonic Operating Company, Inc.
See details and how to joinNCT07473700
Phase 1/2Taking people
Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)
Where
Bydgoszcz, Cracow
Age
18 years and over
People
50 worldwide
Run by
35Pharma Inc.
See details and how to join2025-523010-89-00 · EU 2025-523010-89-00
Phase 3Taking people
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Bialystok, Krakow, Lublin, Warsaw
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07179380 · EU 2025-521558-40-00
Phase 2Taking people
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Where
Bialystok, Bydgoszcz, Cracow, Katowice, Lodz, Poznan
Age
18 years and over
People
99 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07318597 · EU 2024-514754-79-00
No phaseTaking people
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
Where
Warsaw
Age
18 years and over
People
5,000 worldwide
Run by
Azienda Ospedaliero-Universitaria Careggi
See details and how to joinNCT07855679
Phase 3Taking people
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Where
Cracow, Otwock
Age
18 years to 75 years
People
330 worldwide
Run by
Gossamer Bio USA, Inc.
See details and how to joinNCT06274801 · EU 2023-506334-75-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Where
Gdansk, Szczecin, Warszawa
Age
18 years to 75 years
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07481981 · EU 2026-525265-48-00
Phase 2Taking people
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
Where
Cracow
Age
18 years to 80 years
People
40 worldwide
Run by
AllRock Bio, Inc.
See details and how to joinNCT07175038 · EU 2025-522074-37-00
Phase 3Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Where
Bialystok, Poznan, Wrocław
Age
18 years and over
People
1,000 worldwide
Run by
United Therapeutics
See details and how to joinNCT03683186 · EU 2023-509305-68-00
Phase 3Taking people
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Where
Cracow, Katowice, Lodz
Age
18 years to 75 years
People
486 worldwide
Run by
Inhibikase Therapeutics
See details and how to joinNCT07365332 · EU 2024-520218-23-00
No phaseNot yet taking people in Poland
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
Where
Lubin
Age
18 years and over
People
150
Run by
Miedziowe Centrum Zdrowia SA
See details and how to joinNCT07787936
Phase 1/2Taking people
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Where
Poznan
Age
18 years to 100 years
People
232 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06649110
Phase 3Not yet taking people in Poland
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
Where
Cracow, Lublin, Walbrzych, Warsaw, Warszawa
Age
18 years to 75 years
People
300 worldwide
Run by
VIVUS LLC
See details and how to joinNCT07612657 · EU 2025-524596-24-00
No phaseTaking people
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
Where
Kraków
Age
3 months and over
People
3,000
Run by
Polish Cardiology Association
See details and how to joinNCT03959748